{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T16:21:51Z","timestamp":1780849311958,"version":"3.54.1"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ambulatory cancer patients undergoing chemotherapy are at a substantial risk for venous thromboembolism (VTE) over the course of therapy and beyond it. Factors accounting for this risk include the activation of extrinsic and intrinsic coagulation pathways, platelet activation, impaired fibrinolysis, use of catheters, infusion of blood products, and thrombogenic potential of several chemotherapeutic drugs. A few stratification models can help identify patients at a higher risk of chemotherapy-associated VTE, who may benefit from preventive strategies. Although low-molecular-weight heparins (LMWHs) effectively reduce the risk of VTE, current guidelines recommend against their routine use. Based on the results of recent randomized controlled clinical trials, the administration of prophylactic doses of the novel direct oral anticoagulants (DOACs) to ambulatory cancer patients undergoing chemotherapy has the potential to offer an effective and safe protection against VTE, obviating the inconveniences of heparins. Except for patients in whom the novel drugs are unsuitable or are contraindicated, in all other patients LMWHs should be replaced by low-dose DOACs.<\/jats:p>","DOI":"10.1055\/s-0040-1718927","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:28:55Z","timestamp":1611361735000},"page":"914-919","source":"Crossref","is-referenced-by-count":11,"title":["Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: Risk Factors and Prevention"],"prefix":"10.1055","volume":"47","author":[{"given":"Paolo","family":"Prandoni","sequence":"additional","affiliation":[{"name":"Arianna Foundation on Anticoagulation, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campello","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Hospital of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"A T Cohen","year":"2017","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"A A Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jval.2017.09.015","article-title":"What impact does venous thromboembolism and bleeding have on cancer patients' quality of life?","volume":"21","author":"A J Lloyd","year":"2018","journal-title":"Value Health"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"P Prandoni","year":"2005","journal-title":"Lancet Oncol"},{"issue":"26","key":"ref5","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1401468","article-title":"Prophylaxis against venous thromboembolism in ambulatory patients with cancer","volume":"370","author":"J M Connors","year":"2014","journal-title":"N Engl J Med"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1182\/blood-2018-03-837153","article-title":"Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP)","volume":"132","author":"H Decousus","year":"2018","journal-title":"Blood"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"G H Lyman","year":"2013","journal-title":"Oncologist"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/hematology.2019000025","article-title":"Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models","volume":"2019","author":"Y Hisada","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-019-0510-x","article-title":"The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues","volume":"121","author":"E Campello","year":"2019","journal-title":"Br J Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cellsig.2018.04.008","article-title":"Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells","volume":"48","author":"M Zar\u00e0","year":"2018","journal-title":"Cell Signal"},{"issue":"13","key":"ref11","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Y Hisada","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jth.13218","article-title":"Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment","volume":"14","author":"E M Reitter","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref13","first-page":"378","article-title":"Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role","volume":"110","author":"M T Sartori","year":"2013","journal-title":"Thromb Haemost"},{"issue":"20","key":"ref14","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2016-08-693671","article-title":"How I treat central venous access device-related upper extremity deep vein thrombosis","volume":"129","author":"A Rajasekhar","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1160\/TH17-08-0596","article-title":"Contact system activation and cancer: new insights in the pathophysiology of cancer-associated thrombosis","volume":"118","author":"E Campello","year":"2018","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref16","first-page":"63","article-title":"Anti-VEGF agents and the risk of arteriothrombotic events","volume":"7","author":"M A Zarbin","year":"2018","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17474086.2019.1583555","article-title":"Thrombophilia, risk factors and prevention","volume":"12","author":"E Campello","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014","volume":"33","author":"G H Lyman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2015.0133","article-title":"Cancer-associated venous thromboembolic disease, version 1.2015: Featured updates to the NCCN Guidelines","volume":"13","author":"M B Streiff","year":"2015","journal-title":"J Natl Compr Cancer Netw"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"F I Mulder","year":"2019","journal-title":"Haematologica"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"I Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated Thrombosis Study","volume":"22","author":"G T Gerotziafas","year":"2017","journal-title":"Oncologist"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"e1083","DOI":"10.1634\/theoncologist.2019-0482","article-title":"External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model","volume":"25","author":"A C Spyropoulos","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"G Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"G Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"09","key":"ref27","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"A Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"issue":"18","key":"ref28","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"U Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"F Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref30","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"2","author":"M Di Nisio","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"M Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"08","key":"ref32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial","volume":"380","author":"A A Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2018.09.015","article-title":"Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions","volume":"132","author":"H Riess","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3324\/haematol.2019.221424","article-title":"Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients","volume":"105","author":"C Becattini","year":"2020","journal-title":"Haematologica"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.thromres.2005.10.015","article-title":"Chemotherapy-induced thrombosis","volume":"118","author":"T C Haddad","year":"2006","journal-title":"Thromb Res"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2141.1992.tb02978.x","article-title":"Modulation of tissue factor on human monocytes by cisplatin and adriamycin","volume":"81","author":"J Walsh","year":"1992","journal-title":"Br J Haematol"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2214\/AJR.13.11967","article-title":"Vascular toxicity associated with chemotherapy and molecular targeted therapy: what should a radiologist know?","volume":"203","author":"S Rohatgi","year":"2014","journal-title":"AJR Am J Roentgenol"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"E Truelove","year":"2013","journal-title":"Leukemia"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1667\/0033-7587(2000)154[0375:IVAIVE]2.0.CO;2","article-title":"In vitro and in vivo expression of endothelial von Willebrand factor and leukocyte accumulation after fractionated irradiation","volume":"154","author":"E van Kleef","year":"2000","journal-title":"Radiat Res"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdh437","article-title":"Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?","volume":"15","author":"M Erman","year":"2004","journal-title":"Ann Oncol"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0008-6363(03)00468-1","article-title":"The cardiovascular effects of erythropoietin","volume":"59","author":"K J Smith","year":"2003","journal-title":"Cardiovasc Res"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1055\/s-0039-1694763","article-title":"Thrombosis risk in cancer patients receiving red blood cell transfusions","volume":"45","author":"G Ramsey","year":"2019","journal-title":"Semin Thromb Hemost"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1718927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T23:31:54Z","timestamp":1635723114000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1718927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":42,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2021,10,31]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1718927","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]}}}